Travere Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Travere Therapeutics

04/08/2026 22:01

Travere Therapeutics Inc TVTX.OQ reported quarterly adjusted earnings of 6 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -14 cents.  The mean expectation of thirteen analysts for the quarter was for a loss of 14 cents per share. Wall Street expected results to range from -37 cents to 26 cents per share.
Revenue rose 48.2% to $169.58 million from a year ago; analysts expected $159.59 million. 
Travere Therapeutics Inc's reported EPS for the quarter was a loss of 37 cents​.
The company reported a quarterly loss of $34.8 million.
Travere Therapeutics Inc shares had fallen by 3.2% this quarter and gained 43.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 16.7% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Travere Therapeutics Inc is $61.00, about 9.9% above its last closing price of $54.98
This summary was machine generated from LSEG data August 4 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.14
0.06
Beat
Mar. 31 2026 
-0.27
-0.40
Missed
Dec. 31 2025 
-0.12
0.03
Beat
Sep. 30 2025 
-0.21
0.28
Beat